Fresenius Medical Care AG (NYSE:FMS) Receives Consensus Rating of “Hold” from Brokerages

Fresenius Medical Care AG (NYSE:FMSGet Free Report) has received a consensus rating of “Hold” from the seven analysts that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $24.00.

Several research firms recently issued reports on FMS. StockNews.com began coverage on shares of Fresenius Medical Care in a report on Saturday. They issued a “strong-buy” rating on the stock. Truist Financial boosted their target price on shares of Fresenius Medical Care from $21.00 to $24.00 and gave the company a “hold” rating in a report on Wednesday, May 15th.

Check Out Our Latest Stock Report on FMS

Hedge Funds Weigh In On Fresenius Medical Care

Several institutional investors have recently made changes to their positions in the stock. Pacer Advisors Inc. raised its holdings in shares of Fresenius Medical Care by 14,252.1% in the 4th quarter. Pacer Advisors Inc. now owns 488,401 shares of the company’s stock worth $10,173,000 after acquiring an additional 484,998 shares during the last quarter. Envestnet Asset Management Inc. raised its holdings in shares of Fresenius Medical Care by 362.2% in the 3rd quarter. Envestnet Asset Management Inc. now owns 259,033 shares of the company’s stock worth $5,580,000 after acquiring an additional 202,991 shares during the last quarter. Moran Wealth Management LLC acquired a new stake in shares of Fresenius Medical Care in the 4th quarter worth about $3,247,000. Guardian Capital Advisors LP raised its holdings in shares of Fresenius Medical Care by 16.7% in the 4th quarter. Guardian Capital Advisors LP now owns 123,715 shares of the company’s stock worth $2,556,000 after acquiring an additional 17,725 shares during the last quarter. Finally, Partnership Wealth Management LLC acquired a new stake in shares of Fresenius Medical Care in the 4th quarter worth about $2,340,000. Institutional investors and hedge funds own 8.25% of the company’s stock.

Fresenius Medical Care Price Performance

FMS stock opened at $21.30 on Wednesday. The firm has a market cap of $12.50 billion, a price-to-earnings ratio of 23.93, a PEG ratio of 1.13 and a beta of 0.93. The company has a quick ratio of 1.14, a current ratio of 1.50 and a debt-to-equity ratio of 0.46. Fresenius Medical Care has a 12-month low of $16.37 and a 12-month high of $27.72. The company’s fifty day simple moving average is $20.40 and its 200 day simple moving average is $20.20.

Fresenius Medical Care (NYSE:FMSGet Free Report) last released its earnings results on Tuesday, May 7th. The company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.26 by $0.10. The business had revenue of $5.13 billion for the quarter, compared to analyst estimates of $5.15 billion. Fresenius Medical Care had a net margin of 2.48% and a return on equity of 5.29%. On average, analysts expect that Fresenius Medical Care will post 1.51 earnings per share for the current year.

Fresenius Medical Care Cuts Dividend

The business also recently disclosed an annual dividend, which was paid on Monday, June 3rd. Stockholders of record on Monday, May 20th were issued a dividend of $0.437 per share. The ex-dividend date was Friday, May 17th. This represents a dividend yield of 2.35%. Fresenius Medical Care’s dividend payout ratio is currently 49.44%.

Fresenius Medical Care Company Profile

(Get Free Report

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

Featured Stories

Analyst Recommendations for Fresenius Medical Care (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care and related companies with MarketBeat.com's FREE daily email newsletter.